Alexion Pharmaceuticals Inc

ALXN 
(NASDAQ) 
 
$ 119.68 <%= Resources.Global.txtUp %>
Updated 14/08/2018
Change % 1.11% Stock price increasing
Change 1.31 Stock price increasing
Volume 345,635
High $ 120.59
Low $ 118.65
Open $ 118.86
ISIN
Prev close $ 118.37
# of shares 222.86M
Market cap 26,672M USD
Intraday

Market closed
Alexion Pharmaceuticals Inc
Market is closed, opens at 14:30
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  119.68 -0.5% Stock price decreasing -11.9% Stock price decreasing -1.5% Stock price decreasing -2.5% Stock price decreasing -11.5% Stock price decreasing
Powered by TradingView

News about Alexion Pharmaceuticals Inc

  • English
  • Regulatory news

Company profile

Alexion Pharmaceuticals specializes in developing and marketing drugs for life-threatening medical conditions. Its blockbuster product is Soliris, which is the only approved therapy for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, two ultra-rare blood disorders, and was recently approved in general myasthenia gravis. Strensiq and Kanuma target other ultra-rare metabolic diseases. Alexion's pipeline targets areas of high unmet need and complement-mediated disorders.

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
15 August 2018 05:47:21
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180814.1 - EUROWEB5 - 2018-08-15 06:47:21 - 2018-08-15 05:47:21 - 1000 - Website: OKAY